Literature DB >> 31140179

Bioactive Lipids in Inflammation After Central Nervous System Injury.

Rubèn López-Vales1, Samuel David2.   

Abstract

Despite the progress made over the last decades to understand the mechanisms underlying tissue damage and neurological deficits after neurotrauma, there are currently no effective treatments in the clinic. It is well accepted that the inflammatory response in the CNS after injury exacerbates tissue loss and functional impairments. Unfortunately, the use of potent anti-inflammatory drugs, such as methylprednisolone, fails to promote therapeutic recovery and also gives rise to several undesirable side effects related to immunosuppression. The injury-induced inflammatory response is complex, and understanding the mechanisms that regulate this inflammation is therefore crucial in the quest to develop effective treatments. Bioactive lipids have emerged as potent molecules in controlling the initiation, coordination, and resolution of inflammation and in promoting tissue repair and recovery of homeostasis. These bioactive lipids are produced by cells involved in the inflammatory response, and their defective synthesis leads to persistent chronic inflammation, tissue damage, and fibrosis. The present chapter discusses recent evidence for the role of some of these bioactive lipids, in particular, eicosanoid and pro-resolving lipid mediators, in the regulation of inflammation after neurotrauma and highlights the therapeutic potential of some of these lipids in enhancing neurological outcomes after CNS injuries.

Entities:  

Keywords:  Eicosanoids; Inflammation; Neurotrauma; Resolution; Specialized pro-resolving mediators

Mesh:

Substances:

Year:  2019        PMID: 31140179     DOI: 10.1007/978-3-030-11488-6_12

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  6 in total

Review 1.  Neuroinflammation as a Therapeutic Target for Mitigating the Long-Term Consequences of Acute Organophosphate Intoxication.

Authors:  Peter M Andrew; Pamela J Lein
Journal:  Front Pharmacol       Date:  2021-05-12       Impact factor: 5.810

2.  Interleukin-4 and interleukin-13 induce different metabolic profiles in microglia and macrophages that relate with divergent outcomes after spinal cord injury.

Authors:  Jesus Amo-Aparicio; Joana Garcia-Garcia; Isaac Francos-Quijorna; Andrea Urpi; Anna Esteve-Codina; Marta Gut; Albert Quintana; Ruben Lopez-Vales
Journal:  Theranostics       Date:  2021-10-03       Impact factor: 11.556

Review 3.  Functions and mechanisms of cytosolic phospholipase A2 in central nervous system trauma.

Authors:  Hao-Jie Zhang; Yi-Tuo Chen; Xin-Li Hu; Wan-Ta Cai; Xiang-Yang Wang; Wen-Fei Ni; Kai-Liang Zhou
Journal:  Neural Regen Res       Date:  2023-02       Impact factor: 6.058

4.  Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA2), UCM-14216, Ameliorates Spinal Cord Injury in Mice.

Authors:  Nora Khiar-Fernández; Debora Zian; Henar Vázquez-Villa; R Fernando Martínez; Andrea Escobar-Peña; Román Foronda-Sainz; Manisha Ray; Maria Puigdomenech-Poch; Giovanni Cincilla; Melchor Sánchez-Martínez; Yasuyuki Kihara; Jerold Chun; Rubèn López-Vales; María L López-Rodríguez; Silvia Ortega-Gutiérrez
Journal:  J Med Chem       Date:  2022-08-10       Impact factor: 8.039

Review 5.  The Role of Obesity, Inflammation and Sphingolipids in the Development of an Abdominal Aortic Aneurysm.

Authors:  Jakub Okrzeja; Alicja Karwowska; Agnieszka Błachnio-Zabielska
Journal:  Nutrients       Date:  2022-06-12       Impact factor: 6.706

6.  Administration of Maresin-1 ameliorates the physiopathology of experimental autoimmune encephalomyelitis.

Authors:  Alba Sánchez-Fernández; Stephanie Zandee; Mauricio Mastrogiovanni; Marc Charabati; Homero Rubbo; Alexandre Prat; Rubèn López-Vales
Journal:  J Neuroinflammation       Date:  2022-02-02       Impact factor: 8.322

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.